About Rapid Pathogen Screening
Rapid Pathogen Screening is a Healthcare company based in Sarasota (United States) founded in 2004. Point-of-care diagnostic tests for infectious and inflammatory conditions are developed. Rapid Pathogen Screening has raised $35.59 million across 8 funding rounds from investors including Orbimed and Mallitz Investment Group. The company has 7 employees. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Diversified. Its competitors include Inflammatix, Visby Medical and GenMark Diagnostics; 3 of its 3 listed competitors have raised funding.
Company details
Rapid Pathogen Screening was founded in 2004 in Sarasota, United States, and operates in the medical diagnostics sector. Point-of-care tests are developed, manufactured, and commercialized for infectious diseases and inflammatory conditions. In the United States, AdenoPlus detects adenoviral conjunctivitis serotypes, while InflammaDry identifies elevated MMP-9 levels in dry eye disease tears. Internationally, FebriDx differentiates viral and bacterial respiratory infections via fingerstick blood samples.
- Headquarters Sarasota, United States
- Employees 7
- SectorsHealthcare
- Website rpsdetectors.com
- Social LinkedIn
- Legal Name Rapid Pathogen Screening
- Total Equity Funding$35.59M (USD)
in 8 rounds
- Latest Funding Round$1.84M (USD), Series B
Dec 2015
- InvestorsOrbimed
& 1 more
- Employee Count7
Funding Insights of Rapid Pathogen Screening
Rapid Pathogen Screening has successfully raised a total of $35.59M across 8 strategic funding rounds. The most recent funding activity was a Series B round of $1.84 million completed in December 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $35.59M
- Total Rounds 8
- Last Round Series B — $1.84M
- First Round $3.39M
(Feb 2007)
- Investors Count 2
All 8 funding rounds of Rapid Pathogen Screening with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2015 | $1.84M | Series B | – | – | – |
| Oct 2014 | $28M | Debt – Venture | – | – | |
| Jul 2013 | $6.25M | Series B | – | Mallitz Investment Group | – |
| Jul 2013 | $2.28M | Series B | – | – | – |
| Oct 2012 | $6.79M | Series B | – | – | – |
| Jan 2010 | $15M | Series B | – | – | – |
| Jan 2009 | $40,000 | Series A | – | – | – |
| Feb 2007 | $3.39M | Series A | – | – | – |
2 investors in total: 2 institutional.
Investors in Rapid Pathogen Screening
Rapid Pathogen Screening has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Orbimed and Mallitz Investment Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
| mallitzinvestmentgroup.com |
Investor details for Rapid Pathogen Screening
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Rapid Pathogen Screening
3 dated milestones of Rapid Pathogen Screening across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Rapid Pathogen Screening is founded.
- Funding First funding round of $3.4M.
- Funding Latest funding round, Series B, of $1.8M.
Competitors of Rapid Pathogen Screening
Rapid Pathogen Screening has 3 listed competitors in our database, 3 of them funded. They include Inflammatix, Visby Medical and GenMark Diagnostics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| visbymedical.com | 2010 | San Jose, United States | $386.33M | 251 | Portable PCR diagnostics for infectious diseases are developed. | |
| genmarkdx.com | 1993 | San Diego, United States | $8.56M | 797 | Instruments and test panels for multiplexed molecular diagnostics are provided. |
Detailed competitors of Rapid Pathogen Screening
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Rapid Pathogen Screening
Websites that share an audience with Rapid Pathogen Screening (rpsdetectors.com).
Websites whose visitors overlap most with Rapid Pathogen Screening. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
pointofcare.net | pointofcare.net | 100% | – | ||
| tearlab.com | 97% | View details | |||
| midmark.com | 95% | #422,061 | View details | ||
topconmedical.com | topconmedical.com | 95% | – | ||
| allaboutvision.com | 95% | 1.1M | #61,292 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for Rapid Pathogen Screening
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Rapid Pathogen Screening (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rapid Pathogen Screening
Complete news archive for Rapid Pathogen Screening
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rapid Pathogen Screening
Rapid Pathogen Screening was founded in 2004 and raised its 1st funding round 3 years after it was founded.
Rapid Pathogen Screening is headquartered in Sarasota, United States. It is registered at Sarasota, Florida, United States.
Rapid Pathogen Screening is a funded company, having raised a total of $35.59M across 8 funding rounds to date. The company's 1st funding round was a Series A of $3.39M, raised on Feb 2007.
Rapid Pathogen Screening has 7 employees.
Rapid Pathogen Screening was founded in 2004 in Sarasota, United States, and operates in the medical diagnostics sector. Point-of-care tests are developed, manufactured, and commercialized for infectious diseases and inflammatory conditions. In the United States, AdenoPlus detects adenoviral conjunctivitis serotypes, while InflammaDry identifies elevated MMP-9 levels in dry eye disease tears. Internationally, FebriDx differentiates viral and bacterial respiratory infections via fingerstick blood samples.
Rapid Pathogen Screening's top competitors include Visby Medical, Inflammatix and GenMark Diagnostics.
Rapid Pathogen Screening has 2 investors. Key investors include Orbimed, and Mallitz Investment Group.
Rapid Pathogen Screening operates through Rapid Pathogen Screening.